Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$16.04 USD
-0.08 (-0.50%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $16.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ROIV 16.04 -0.08(-0.50%)
Will ROIV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Other News for ROIV
Is ROIV showing downside potential? MACD Bearish Signal Line Cross shows up after sinking 0.5%
ROIV rises 0.56% on October 9, leaving the technical picture intact
ROIV falls 0.56% on October 8, leaving the technical picture intact
Slingshot Bullish appears for ROIV after 0.86% move
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)